The Journal of Arthroplasty 34 (2019) S225–S237

Contents lists available at ScienceDirect

The Journal of Arthroplasty

journal homepage: www.arthroplastyjournal.org

General Assembly, Treatment, Antimicrobials: Proceedings of International Consensus on Orthopedic Infections

K. Keely Boyle [1], Feng-Chih Kuo [2], Juan Pablo Horcajada [3], Harriet Hughes [4], Luca Cavagnaro [5], Camelia Marculescu [6], Alex McLaren [2], Scott R. Nodzo [1], Giovanni Riccio [5], Parham Sendi [5], Randi Silibovsky [1], John Stammers [3], Timothy L. Tan [6], Matthias Wimmer [6]

ARTICLE INFO

Article history:
Available online 22 October 2018

Keywords:
treatment
antibiotic duration
polymicrobial periprosthetic joint infection
antibiotic alternatives
resistant microorganisms
minimum inhibitory concentration
minimum biofilm inhibitory concentration
minimum biofilm bactericidal concentration
methicillin-resistant *Staphylococcus epidermidis*
Clostridium difficile
Enterococcus
rifampicin resistance
gram-negative PJI
fungal PJI
Cutibacterium acnes
Mycobacterium tuberculosis
amphotericin B

Question 1: What is the optimal choice and duration of antibiotic therapy in polymicrobial PJI/SSI?

Recommendation:

The optimal choice and duration of antimicrobial therapy in polymicrobial PJIs remain unknown. Antimicrobial therapy for polymicrobial PJI should be targeted at the organisms that are present. There is limited literature on the antibiotic treatment as polymicrobial PJIs are very heterogenous. We recommend 4-6 weeks of intravenous, or highly available oral antimicrobial therapy, that is based on the in vitro susceptibilities of the individual microorganisms, patient allergies, and intolerances.

Level of Evidence: Limited

Delegate Vote: Agree: 92%, Disagree: 5%, Abstain: 3% (Super Majority, Strong Consensus)

Rationale:

Polymicrobial periprosthetic joint infection (PJI), as identified by isolation of multiple organisms by culture, constitutes between 6% and 37% of reported PJI [1–4]. Patients with polymicrobial PJI have worse outcomes when compared to monomicrobial PJI and culture-negative PJI regardless of the surgical treatment [5,6]. Studies have shown lower success rates of polymicrobial PJIs (37%-67%) compared to that of monomicrobial PJIs (69%-87%) [5–9]. The treatment often requires broad-spectrum antibiotics or multiple antibiotics given that multiple organisms need to be targeted. Unfortunately, there is minimal literature regarding the optimal choice and duration of antibiotic therapy in patients with polymicrobial PJI. This is largely due to the fact that polymicrobial PJIs are very heterogenous and may represent many combinations of infecting organisms including fungi. However, there are many studies that have demonstrated that polymicrobial PJIs are associated with certain bacteria. Marculescu and Cantey found that methicillin-resistant *Staphylococcus aureus* (26.4% vs 7.1%) and anaerobes (11.7% vs 2.8%) were more common in polymicrobial PJIs. In addition, Tan et al reported that the isolation of Gram-negative organisms ($P < .01$), enterococci ($P < .01$), *Escherichia coli* ($P < .01$), and atypical organisms ($P < .01$) was associated with polymicrobial PJI. Furthermore, many of these organisms are associated with high failure rates and the optimal antimicrobial for these organisms is still being defined [10,11].

Although there are no randomized studies to compare the duration of treatment for polymicrobial PJIs compared to monomicrobial PJIs, patients treated for polymicrobial PJIs received 4-6

One or more of the authors of this paper have disclosed potential or pertinent conflicts of interest, which may include receipt of payment, either direct or indirect, institutional support, or association with an entity in the biomedical field which may be perceived to have potential conflict of interest with this work. For full disclosure statements refer to https://doi.org/10.1016/j.arth.2018.09.074.

[1] Question 3.
[2] Question 6.
[3] Question 2.
[4] Question 4.
[5] Question 5.
[6] Question 1.

https://doi.org/10.1016/j.arth.2018.09.074
0883-5403/

weeks of antimicrobial therapy [6–8], with the choice of an initial 2 weeks of parenteral antimicrobial therapy followed by 4 weeks of oral and highly bioavailable antibiotic therapy [7,8]. Current Infectious Diseases Society of America guidelines, while not specifically addressing polymicrobial PJIs, suggest 4-6 weeks of pathogen-specific intravenous or highly bioavailable oral antimicrobial therapy, which does not differ from the treatment of monomicrobial PJIs [12].

A study done by Moran et al [3] on 112 patients showed that polymicrobial organisms were present in 46.7% in the early postoperative period (within 3 months after prosthesis implantation). Although in this study Gram-negative organisms were seen only in 8% of the polymicrobial isolates, among these isolates were organisms classically associated with chromosomal Amp C inducible beta-lactamases (*Enterobacter cloacae*, Serratia spp, *Morganella morganii*) and resistant Acinetobacter spp. These findings along with a high rate of beta-lactam resistance among coagulase-negative staphylococci have led the authors to recommend a broad-spectrum empirical antimicrobial coverage with a glycopeptide and a carbapenem [3]. In contrast, a study by Sousa et al [13] found no increased prevalence of polymicrobial infection in the early postoperative period, but they too recommend a carbapenem and vancomycin as empirical antimicrobial therapy for chronic and hematogenous infections when polymicrobial infection was present.

When selecting empirical antimicrobial therapy for polymicrobial PJIs, it is therefore important to be aware of the local and institutional Gram-negative and Gram-positive resistance pattern. Broad-spectrum antimicrobials should be stopped as soon as susceptibility results are available, and effective antimicrobials with the narrowest spectrum of activity should be selected for completing the therapy.

Given that outcomes are poor with polymicrobial PJIs, chronic suppression may be warranted as multiple studies have demonstrated increased survivorship with the addition of oral antibiotics [14,15]. Frank et al [14] demonstrated that patients treated with oral antibiotics failed secondary to infection less frequently than those not treated with antibiotics (5% vs 19%; $P = .016$) in a prospective randomized controlled trial.

Search Methodology

A PubMed search for the MeSH terms ((“Infection” [Mesh]) AND (“Prostheses and Implants” [Mesh] OR “Prosthesis Implantation” [Mesh] OR “Prosthesis-Related Infections” [Mesh] OR “Prosthesis Failure” [Mesh])) AND “Coinfection” [Mesh] as well as for the terms polymicrobial [All Fields] AND (“joints” [MeSH Terms] OR “joints” [All Fields] OR “joint” [All Fields]) AND (“infection” [MeSH Terms] OR “infection” [All Fields]) on February12, 2018 revealed a total of n = 161 results. All publications were screened and evaluated for relevance regarding the research question and duplicates.

Question 2: What systemic antibiotic therapies should be used in patients with SSI/PJI caused by resistant organisms?

Recommendation:

The choice of antibiotic therapy in patients with surgical site infection or periprosthetic joint infection (SSI/PJI) caused by resistant organisms is not fully answered by literature. There are a number of antibiotic choices available for patients with SSI/PJI caused by resistant organisms. The antibiotic selection process should consider patient comorbidities, mode of administration, risk of *Clostridium difficile*, need for monitoring, allergy profile of the patient, intolerance, regional resistance patterns, cost, and availability. Ideally, apart from having activity against the resistant organisms, antibiotic choice should have good bone and soft tissue penetration and activity against biofilm. Consultation with infectious diseases specialists and clinical microbiologists is warranted in these cases.

Level of Evidence: Limited

Delegate Vote: Agree: 96%, Disagree: 2%, Abstain: 2% (Unanimous, Strongest Consensus)

Rationale:

Success rates in the treatment of periprosthetic joint infection (PJI) produced by resistant bacteria are lower than those from sensitive organisms, resulting in an increase in morbidity and cost. Successful treatment requires a multidisciplinary approach, including orthopedic surgeons, infectious diseases specialists, and microbiologists with an interest and experience in treating these complex infections.

Relative resistance is conferred by biofilms even when treated with susceptible antimicrobials, particularly in debridement and implant retention (DAIR). Antimicrobial decision making needs to consider not only the minimum inhibitory concentration but also the minimum biofilm inhibitory concentration and minimum biofilm bactericidal concentration, if performed.

Staphylococcus, Streptococci, Enterococci, enterobacteriae such as *Escherichia coli* or *Klebsiella pneumoniae*, *Pseudomonas*, and *Candida* are common microorganisms that form biofilms and are implicated in PJI [16]. The biofilm results in physiological, physical, and adaptive resistance mechanisms to commonly used antibiotics in PJI including aminoglycosides, β-lactams, quinolones, and glycopeptides [17].

The transcriptional inhibitor rifampicin has demonstrated consistent antibiofilm activity in Gram positives and is recommended by the Infectious Diseases Society of America (IDSA). Fluoroquinolones are the first choice as antibiofilm agent in Gram-negative infections. Colistin and fosfomycin could be alternatives [16].

Gram-Positive Periprosthetic Joint Infection/Surgical Site Infection

The main Gram-positive PJIs are *Staphylococcus aureus* and *Staphylococcus epidermidis*. Methicillin resistance is more common in *S epidermidis* (MRSE) compared to *S aureus* (MRSA). The majority of clinical studies include both MRSA and MRSE sharing treatment options. *Enterococcus* spp. is a rare cause of Gram-positive PJI including vancomycin-resistant enterococcus.

The initial therapy of MRSA or MRSE PJI infections after debridement should be directed against planktonic cells and is currently based in glycopeptides [18]. However, at high inocula vancomycin’s efficacy is often suboptimal, and in monotherapy poor clinical data have been published [19]. Interestingly, the combination of daptomycin plus oxacillin has shown synergy in vitro MRSA models, also against biofilm-embedded bacteria [20–22]. Although clinical experience is lacking, this combination could be used in the first days of MRSA PJI infection.

After the initial acute period (1-2 weeks), targeted antibiofilm therapy is warranted. As stated previously, rifampicin has excellent activity against staphylococci in biofilm [23]. There is some indication that rifampicin in combination with other anti-Staphylococcal agents may improve the outcome of treatment. This was highlighted by one of the few clinical randomized controlled trials on antibiotic use in PJI. In patients with staphylococcal infection surgically managed by DAIR, the addition of rifampicin to flucloxacillin or vancomycin for 2 weeks and 3-6 months of ciprofloxacin improved cure rate from 58% to 100% compared to antibiotics with a rifampicin placebo [24]. The latter study has been criticized for consisting of a very small number of patients and its findings have not been embraced by the entire orthopedic community. It is important to note that rifampicin monotherapy is associated with a

high likelihood of resistance and is not recommended by IDSA guidelines. Many methicillin-resistant staphylococcal PJIs are also resistant to fluoroquinolones; however, if susceptible it combines well with rifampicin with good outcomes [24–27]. This combination has a good bioavailability, activity, and safety, as has been shown in several clinical studies, and it is considered the first choice if the *Staphylococcus* is susceptible to both agents [24,26–29].

There are numerous combinations with rifampicin suggested in the literature for resistant staphylococci and alternatives if rifampicin cannot be used. The majority of clinical studies are noncomparative retrospective reviews. The animal studies and in vitro studies provide comparative results but there is little consensus and different methodologies used limit meta-analysis to make conclusions. A number of studies compare the following agents in combination with rifampin: vancomycin, daptomycin, linezolid, cephalosporins, carbapenems, fosfomycin, tigecycline, minocycline, fusidic acid, and co-trimoxazole. Vancomycin is often the first line in MRSA/MRSE PJI [30]. A number of studies have concluded that year-on-year MRSA strains have a higher vancomycin minimum inhibitory concentration [31,32]. Some studies have demonstrated improved efficacy with vancomycin and rifampicin in vitro [33] but this combination also results in rifampicin resistance [34]. In comparison to levofloxacin, daptomycin has favorable results when combined with rifampicin in vitro. Monotherapy use produced rifampicin and daptomycin resistance and should be avoided [35,36]. Compared with linezolid and vancomycin, animal studies similarly favored daptomycin and rifampicin [36–38]. A similar animal study comparing linezolid, vancomycin, and daptomycin as a monotherapy and in combination concluded superiority of the daptomycin-rifampicin combination [39]. Clinically, noncomparative series using daptomycin achieved good outcomes if the implant is removed with 91% (10/11) [40] and 100% (22/22) [41] success with 2-stage revision, respectively. Poor results occurred after DAIR using daptomycin and rifampicin, with success rates ranging from 50% to 80% (4/5 [40] (6/12, [42]) (9/18, [43]).

The 5th generation cephalosporin, ceftaroline, is an option with similar activity to vancomycin and improved side effect profile. It is more effective in combination with rifampicin in MRSA animal models [44]. An in vitro biofilm study, in contrast, concluded that the addition of rifampicin to ceftaroline was not beneficial and antagonistic with some MRSA strains. They found that ceftaroline and daptomycin combination was the most effective but accepted that in vivo studies were required before its clinical applicability is known [45].

Tigecycline has been investigated as an alternative in MRSA PJI. Animal models comparing it to vancomycin as monotherapy or combined with rifampicin concluded that it was as effective as vancomycin with rifampicin but tigecycline alone was least effective [46]. Tigecycline combined with other antimicrobials produces an indifferent response but has been shown to be effective against multiresistant Gram-positive and Gram-negative organisms and could be considered as part of a combination regimen when first and second-line options are contraindicated [47,48].

Thompson et al compared 10 antibiotic groups in an MRSA animal model. The study did not confirm superiority but that linezolid, vancomycin, daptomycin, ceftaroline in combination with rifampicin were successful at eradicating bacteria. No antibiotic monotherapy cleared the bacteria [49].

In comparison to the oral antimicrobials—fusidic acid, linezolid, rifampicin, and minocycline—linezolid was the only monotherapy effective against biofilm-embedded MRSA [50]. In an animal methicillin-sensitive Staphylococcus aureus (MSSA) model, linezolid with rifampicin prevented rifampicin resistance and demonstrated superior activity compared to linezolid alone or cloxacillin with or without rifampicin [51].

The retrospective clinical results of linezolid with rifampicin following DAIR achieved successful remission in 69% (34/49). Linezolid was used as second line where previous treatment failed or due to therapy intolerance [52].

In another retrospective review of 39 Gram-positive cocci PJI, remission of infection was achieved in 72% using linezolid following DAIR. Some patients also received rifampicin which in this series was associated with a higher failure rate of 36% vs 18% which the authors commented that the rifampicin group had a higher proportion of MRSA, diabetes, and longer symptom duration before DAIR [53].

Combinations of rifampin plus linezolid have shown an increase in the antibacterial effect of linezolid in biofilm, and a synergic activity against MRSA isolates [34,50,51]. Clinical series have demonstrated acceptable clinical outcome, although the studies are heterogeneous [52–54]. The possible effect of rifampin in the metabolism of linezolid is not well established. In vivo studies such as Gandelman et al [55] showed that the combination is safe and well tolerated with only a small effect on the clearance of linezolid.

Results of co-trimoxazole and fusidic acid highlight that they still have a role in resistant staphylococcal PJI. Lower cost and oral administration are advantageous if the microorganisms are susceptible. A study of 56 bone and joint infections including 36 with infected implants received either linezolid or co-trimoxazole in combination with rifampicin. There was no significant difference in cure rates with 89.3% success with linezolid and 78.6% with co-trimoxazole [56]. Co-trimoxazole has historically been an oral agent active against resistant staphylococcal infections achieving success in 67% in a prospective study of 39 PJIs. Treatment was between 6 and 9 months. Device removal improved outcomes but 60% were successful with implant retention [57].

A large retrospective review of 345 *S aureus* PJIs managed with DAIR concluded that there was no difference in success between β-lactams or quinolones for MSSA or glycopeptides, co-trimoxazole, linezolid, or clindamycin for MRSA in a series where 88% were used in combination with rifampicin. Overall success was 55%, of which 80% had received rifampicin for over 4 weeks [26].

Options in Rifampicin Resistance

Rifampicin resistance in association with resistant organisms is associated with inadequate surgical debridement or inadequate combination antibiotic treatment [58]. The IDSA recommend a 4- to 6-week intravenous (IV) course of anti–biofilm-guided therapy in rifampicin resistance [12].

Fosfomycin has been investigated as an alternative to rifampicin in Gram-positive resistant PJI. Vancomycin with fosfomycin or rifampicin was superior to tigecycline for planktonic bacteria, and vancomycin combinations with fosfomycin or minocycline were superior for antibiofilm activity [33]. Fosfomycin with daptomycin was as effective as daptomycin-rifampicin. Fosfomycin-imipenem was ineffective and resulted in resistance [38]. An in vitro biofilm comparison model found higher rifampicin resistance with vancomycin, teicoplanin, daptomycin, and tigecycline [34]. A similar model used the same antibiotics, except daptomycin, but combined them with fosfomycin. They concluded that fosfomycin enhanced activities of linezolid, minocycline, vancomycin, and teicoplanin, and was superior to rifampicin combinations [59].

Interestingly, an animal model study suggested that rifampicin resistance can be transient and that rifampin-based combination therapy can be effective even if rifampin-resistant bacteria were previously selected by rifampin exposure [60].

Some studies have even demonstrated that using resistant antibiotics in combination with a nonresistant antibiotic may be effective. Combining cloxacillin with daptomycin was active in an

MRSA animal model [20] and was as effective as cloxacillin with rifampicin in an MSSA model in rifampicin resistance [21]. In vitro and in vivo laboratory studies have demonstrated synergy between daptomycin and β-lactams or carbapenems including nafcillin, cefotaxime, amoxicillin-clavulanic, and imipenem. Combination therapy prevented daptomycin resistance [22]. An in vitro MRSA biofilm study concluded that neither daptomycin nor linezolid was active against biofilm-embedded bacteria; however, in combination they were successful [61]. In other studies, linezolid monotherapy exhibited excellent inhibitory effects against biofilm-embedded MRSA [34,59]. There is considerable literature on the use of linezolid in monotherapy, showing high success rates [53,59–64]. Its excellent bone and tissue penetration is one of the main reasons for this. Therefore, it could be an alternative in rifampin-resistant staphylococcal infections.

Drug Interaction and Concentration Levels

Although the majority of studies demonstrate a benefit from combination therapy, drug interactions and pharmacokinetics must be considered. A randomized controlled trial comparing fusidic acid with rifampicin vs vancomycin was stopped. The authors identified that the fusidic acid concentrations were lower than expected, and at low levels rifampicin resistance occurred [65]. In contrast, a study of 62 patients taking rifampicin and fusidic acid demonstrated pharmacokinetics resulting in high drug exposure [66]. Decreased trough clindamycin concentrations were associated with concomitant rifampicin use in an observational study of 61 patients infected with Gram-positive organisms [67]. A crossover study into the pharmacokinetics of linezolid in combination with rifampicin in 16 healthy adults demonstrated an interaction resulting in increased linezolid metabolism resulting in a lower concentration for the dosing interval [55].

Enterococcus

Enterococcal PJI is rare (3%-10%) and associated with high failure rates [68]. Unlike rifampicin in staphylococcal PJI, there is no antibiofilm agent active against enterococcus. Strains can be penicillin susceptible, penicillin resistant, or vancomycin resistant. IDSA guidelines recommend combination therapy with aminoglycosides. Typical combinations of gentamicin with ampicillin for penicillin susceptible, vancomycin for penicillin resistant, and linezolid or daptomycin for vancomycin resistant are recommended. In vitro and animal studies of *Enterococcus faecalis* had cure rates of 17% with vancomycin, 25% with daptomycin, 33% with vancomycin and gentamycin, and 55% with daptomycin and gentamycin [69]. Fosfomycin with gentamicin was shown to be superior to vancomycin and daptomycin with eradication of *E faecalis* in 42%. Combinations of cephalosporins, ampicillin, aminoglycosides, daptomycin, and linezolid are options for vancomycin-resistant enterococcus PJI but there is no consensus across the literature and clinical series are too small and heterogenous to make firm conclusions on antibiotic therapy. Due to the low success treating these resistant organisms that lack antibiofilm therapy, DAIR is unlikely to work and aggressive surgical management is required.

Gram-Negative Periprosthetic Joint Infection/Surgical Site Infection

In total, 10%-30% of PJIs are caused by Gram-negative bacteria. These include *E coli*, *Pseudomonas aeruginosa*, Klebsiella species, Proteus species, Pasteurella species, and Serratia spp [70,71]. Appropriate antibiotics include cephalosporins, carbapenems, and fluoroquinolones often in combination, directed by antibiofilm including fluoroquinolones in the combination when susceptible. Colistin and fosfomycin have good biofilm activity and can be used in combination, particularly against fluoroquinolone-resistant organisms. Extended-spectrum β-lactamase producing *Enterobacteriaceae*, *Klebsiella pneumoniae carbapenemase*-producing (KPC) *Enterobacteriaceae*, and *Pseudomonas* strains are resistant to a variety of antibiotics and are difficult to eradicate.

Like the biofilm in Gram-positive organisms, many Gram-negative organisms demonstrate resistance to phagocytosis when adherent to the surface of implants even when treated with susceptible antibiotics. Clinical outcomes of Gram-negative PJI in the literature vary between high rates of success, even following DAIR or small series of very difficult to treat infections where despite combination antibiotics and aggressive surgical management with staged revision they have low rates of success. Fluoroquinolone sensitivity or resistance explains the dichotomy. Fluoroquinolones have good activity against *E coli* due to efficacy against nongrowing and adherent bacteria [72]. A retrospective series of 17 Gram-negative infections managed with DAIR achieved successful remission in 15. Antibiotic use included IV cephalosporins or carbapenems initially followed by medium-term oral ciprofloxacin. The authors concluded that the ciprofloxacin provided good antibiofilm activity [73]. A retrospective review of 24 Gram-negative bone infections successfully eradicated infection in 79% using a combination of cefepime and fluoroquinolone. Approximately half were treated with device retention and half with removal but there was no difference in success [74]. Ceftazidime and ciprofloxacin combination therapy was effective with implant retention in 24 pseudomonas infected implants [75]. A large retrospective series of 242 Gram-negative PJI infections also demonstrated that including fluoroquinolones in the combination therapy had higher successful rates [76].

Carbapenem-resistant *K pneumoniae* has advanced mechanisms to rapidly generate resistance on therapy, including colistin and aminoglycosides. A failure to respond to treatment warrants not only a change in antibiotics but repeated debridement and new samples for sensitivity testing [77]. An animal model of KPC-producing *Enterobacteriaceae* demonstrated that synergistic combinations of tigecycline with rifampicin or gentamicin were effective, whereas there was antagonism using a combination of tigecycline with meropenem or colistin [78].

An in vitro and animal study of fluoroquinolone-resistant *E coli* comparing fosfomycin, colistin, tigecycline, and gentamycin, alone and in combination, concluded that the highest cure rate was with fosfomycin and colistin. Fosfomycin was the only monotherapy able to eradicate extended-spectrum β-lactamase-producing *E coli* biofilms [79].

IDSA guidelines recommend combination therapy for *Pseudomonas* PJI due to the limited antibiotic options [12]. In vitro studies combining fluoroquinolones with β-lactams or aminoglycosides reduce the risk of resistance to Pseudomonas and Acinetobacter spp [80,81]. Multidrug-resistant *Pseudomonas* was more effectively treated by combination therapy of colistin with β-lactams (cure rate 11/15) compared to monotherapy (cure rate 6/19) [82].

Interestingly, combining drugs even if one of them is resistant can be associated with antimicrobial activity. An in vitro study of biofilm and planktonic multidrug-resistant *P aeruginosa* concluded that colistin in combination with doripenem was effective against both carbapenem susceptible and resistant strains and reduced colistin resistance. The role of the carbapenem is to prevent colistin resistance, not treat the resistant organism [83].

Some newly approved antibiotics for resistant Gram-negative infections utilize the synergy of antibiotic combinations. Ceftazidime/avibactam and ceftolozane/tazobactam combine second-generation β-lactamase inhibitors with cephalosporins. In vitro

activity is demonstrated against multiple drug-resistant Gram-negative organisms including *Pseudomonas* and KPC-producing *Enterobacteriaceae*. Clinically, they are licensed for ventilator-associated pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections [84]. Currently, there are no studies specifically using these novel drugs in PJI.

Fungal Periprosthetic Joint Infection

Less than 1% of PJIs are due to fungal infections. They are often associated with multiple revisions for infection, immunosuppression, and prolonged antibiotic therapy [85,86]. *Candida* is the most common species and is known to produce a complex biofilm conferring rapid resistance. IDSA guidelines recommend fluconazole initially but ultimately based on antifungal susceptibility testing. Antibiofilm activity can require high antifungal doses associated with systemic toxicity, therefore staged arthroplasty and use of antifungal bone cement is routinely advocated. Amphotericin B [87] or voriconazole [88] is heat stable and achieve high local concentrations.

Question 3: Should PJI caused by *C. acnes* be treated the same as other bacterial causes of PJI?

Recommendation:

Yes. Periprosthetic joint infections (PJI) caused by *C. acnes* should be treated in the same fashion as other causes of PJI.

Level of Evidence: Moderate

Delegate Vote: Agree: 94%, Disagree: 4%, Abstain: 2% (Super Majority, Strong Consensus)

Rationale:

Cutibacterium *acnes* is a nonspore-forming, Gram-positive, facultative bacillus classified as an anaerobe with aerotolerant properties [89–91]. *C acnes* has previously been categorized as a laboratory handling contaminant and considered nonpathogenic, largely due to the presumed commensal nature of the bacterium, as well as identification on normal skin flora and maintenance of the microbiome [90,92]. Despite previous thinking, *C acnes* is becoming increasingly recognized as an opportunistic and pathogenic organism in orthopedic surgery. *C acnes* often presents in a subacute or delayed manner due to an indolent clinical presentation and unreliable utility of classically used markers of infection; however, this organism may represent 6%-10% of orthopedic infections [90,93–97]. It is speculated that *C acnes* colonizes the surgical site at the time of prosthesis implantation, and grows unrecognized by the body through biofilm formation [98–100]. In the shoulder, the clinical and traditional inflammatory laboratory indicators of infection with *C acnes* are often within normal limits; however, its presentation during hip and knee arthroplasty infection may be more overt with classical signs and symptoms of infection [96,101]. Accurate identification of *C acnes* requires long hold cultures up to 14 days, which is likely why this organism has previously been under-appreciated as the cause of orthopedic infections [90,91].

In the orthopedic literature, *C acnes* has been identified as both a possible commensal organism observed at the time of surgery and as a definite pathological bacterium implicated in orthopedic implant-related infections. One prospective study evaluating intraoperative cultures showed *C acnes* to be present in 8.5% of skin cultures, 7.6% of superficial cultures, and 13.6% of deep cultures at the time of primary shoulder surgery [102]. The prevalence of *C acnes* in patients undergoing revision shoulder arthroplasty has been shown to exceed that of other common offending organisms, with a recent study showing 38% of patients having a positive *C acnes* culture [103]. A recent study utilizing next-generation sequencing in patients presumed to be undergoing aseptic revision hip and knee arthroplasty isolated microbial DNA in 27% of patients with *C acnes* being the most prevalent organism [104].

Previous work has attempted to distinguish between these commensal and pathogenic strains through phylotype associations, and phenotypic markers of the bacteria such as hemolysis [105,106]. A distinct pathogenic phenotype has yet to be clearly associated with true clinical infections; however, phylotypes IB and II have most commonly been implicated in orthopedic infection [105]. These phylotypes have varying adaptive virulence properties that may influence pathogenic potential, including the ability to degrade and invade host cells, produce an enhanced host inflammatory response, form biofilms, and demonstrate antibiotic resistance [107–109]. Beta-hemolytic activity has been noted in certain strains of *C acnes* and may be directly correlated with the bacteria's pathogenicity [106]. The hemolytic Christie-Atkins-Munch-Peterson factor is found in the *C acnes* genome and functions as a toxin to host cells, which may be responsible for this observed beta-hemolytic activity [108,110]. A *C acnes* hemolytic phenotype observed on *Brucella* blood agar media has been shown to be a marker of definite infection with 100% specificity and 80% sensitivity along with an increased pattern of antibiotic resistance [106,111]. Suggestions of enhanced virulence of *C acnes* have been implicated when it serves as a coinfectant with other bacterial species, which may be why at times it is found in polymicrobial cultures, and erroneously characterized as a contaminant in some clinical situations [112,113].

Pathogenic *C acnes* strains are well known to form a robust biofilm on implant surfaces resistant to antibiotic penetration, similar to more commonly recognized bacterial pathogens [108,114,115]. Implant biofilm is difficult to treat without implant removal, and reported treatment success of a *C acnes* PJI has been variable with treatments involving implant or polyethylene retention having the poorest results [101,116,117].

Currently, there are no prospective studies evaluating varying treatment strategies of *C acnes* orthopedic infection, with most studies being retrospective in nature. Retrospective studies evaluating various treatments for shoulder, hip, knee, and spine *C acnes* infection have reported variable success [101,116–118]. Studies evaluating total shoulder arthroplasty and upper extremity infection have shown good outcomes with treatments involving 1- or 2-stage revision procedures with success rates ranging from 74% to 95% [93,101,119,120]. One retrospective analysis found that nonsurgical treatment with 4-6 weeks of IV antibiotics led to 67% of patients not requiring subsequent surgical management compared to 71% of patients not requiring further surgery after initial surgical management [121]. Two studies evaluating all orthopedic infections caused by *C acnes* reported a 100% failure rate when partial or no implant removal was performed with success rates ranging from 62% to 75% when 1- and 2-stage exchanges were performed [116,117]. A similar retrospective study evaluating hip, knee, and shoulder arthroplasty PJI with *C acnes* showed a 95% success rate in total shoulder arthroplasty PJI treated with a 2-stage procedure, while those treated with an irrigation and debridement with component retention (I&D) had a 37% success rate [101]. Hip and knee success rates in the same study were lower when a 2-stage procedure was utilized at 67% and 64%, respectively. However, other studies have reported success rates as high as 94%-100% with a 2-stage exchange for hip and knee PJI with *C acnes* [101,118]. One retrospective study specifically evaluated *C acnes* total knee arthroplasty (TKA) PJI treated primarily with 2-stage exchange and I&D with liner exchange compared to methicillin-sensitive staphylococcal TKA PJI. This study showed similar success rates between treatment groups and suggested a PJI treatment strategy similar to MSSA TKA PJI be performed for *C acnes* TKA PJI [96].

C acnes has also been noted as a common pathogen in spine surgery with one large study showing *C acnes* representing 9.7% of positive cultures [97]. Similar treatment strategies with partial and

complete hardware exchange have been evaluated in the literature with patients having partial implant removal resulting in inferior infection eradication rates compared to those patients who had complete exchange of spinal components [97,122].

C acnes is usually susceptible to beta-lactams, quinolones, clindamycin, and rifampin, but resistance is emerging and antibiotic susceptibility testing should be considered for PJI [111]. There is no general consensus on how to treat these infections. Many recommend 3-6 months of antibiotic treatment, including 2-6 weeks of IV treatment with a beta-lactam, but no randomized controlled trials have been performed and some studies favor shorter treatment durations [108]. Given the lack of randomized controlled trials, following the Infectious Diseases Society of America guidelines of 4-6 weeks duration is recommended [123].

The role of rifampin is also unclear. An in vitro study showed activity against *C acnes* biofilms [124]. One low-quality retrospective cohort study in patients with a primary or revision joint arthroplasty of the shoulder, hip, or knee evaluated the role of rifampin in combination therapy and showed no difference in treatment success [125]. There are currently no randomized controlled human studies on the efficacy of rifampin in combination antimicrobial treatment for *C acnes* PJI. Given the limited data, the addition of rifampin to the treatment regimen is not recommended at this time.

Although no prospective studies are currently available regarding the optimal treatment strategy for *C acnes*, careful review and synthesis of the available literature suggest that *C acnes* be considered a true pathogen when the appropriate constellation of findings are present. When *C acnes* PJI is identified, treatment algorithms should model after those of other invasive offending organisms. Caution should be taken when treating *C acnes* PJI without explantation of exchangeable components or efforts to eliminate biofilm on retained implants due to the low success rates of simple I&D with component retention.

Question 4: What is the most effective antibiotic in the treatment of *Cutibacterium acnes* PJI?

Recommendation:

Unknown. High rates of susceptibility to narrow spectrum beta-lactams make these a good initial intravenous option, though the optimum oral switch is not known. The role of rifampicin is controversial. Prospective clinical studies are required to determine the optimal antimicrobial therapy for *C. acnes* PJI.

Level of Evidence: No Evidence

Delegate Vote: Agree: 93%, Disagree: 2%, Abstain: 5% (Super Majority, Strong Consensus)

Rationale:

Cutibacterium acnes is an anaerobic Gram-positive bacillus and a common skin commensal found deep in sebaceous glands and hair follicles. As well as being commonly implicated in acne vulgaris, it is a well-recognized pathogen of device-related infection including prosthetic joints [108,116,126,127].

The ability of *C acnes* to form biofilm is a major virulence factor in the development of these infections, including PJI, and is an important consideration for optimizing treatment strategies. Management should follow well-recognized guidelines of a combination of surgery and targeted antibiotic therapy [68,128,129], although this has been challenged by at least one retrospective analysis [121]. Pragmatically, however, without doing prospective studies and controlling for the surgery performed, the duration of therapy, and individual host factors, comparisons of different antibiotic regimens in the real world are very difficult.

This problem is compounded by the difficult issue of determining the significance of cultured *C acnes* from orthopedic specimens, as it is a common and well-recognized contaminant. It has been shown to be present in fluid washed across the skin incision [100], has been found on surgeons' gloves after handling the subdermal layer [130], and is not reliably removed from the skin by surgical skin antisepsis [131]. The multiple sampling method of Atkins et al [132] is commonly used to aid interpretation of the significance of *C acnes* isolates, with one specimen positive out of 3-5 usually being deemed a contaminant [132]. The recommended duration of incubation of enrichment broths has been extended in recent years to 10-14 days to improve the pick-up rate of relatively slow growing *C acnes* in these samples. By increasing the isolation of significant isolates, however, the rate of contaminants also increases and requires careful interpretation [133]. It has been suggested that those isolated from true infections flag earlier than those that represent contamination. Sonication is recommended by some to improve pick-up rates of *C acnes* associated with biofilm [134]. Some authors have gone further, by creating scoring systems to aid identification of true *C acnes* infections [116,127].

For these reasons, accurate identification of *C acnes* PJIs retrospectively is fraught with difficulties, and thus interpretation of the outcome data comparing treatment strategies is very limited. The clinical details are imperative to aid interpretation. As well as varying in the clinical information available, retrospective studies also often span many years or decades, and straddle changes to sampling methods, culture methods, and recommended duration of enrichment cultures. These differences further limit the ability to draw detailed comparisons between different interventions.

In vitro susceptibilities of *C acnes* are reported widely. Surveillance studies show that it remains susceptible to many antibiotics commonly used in the treatment of bone and joint infection, but with increased and variable resistance to macrolides, clindamycin, tetracyclines, and trimethoprim-sulfamethoxazole. A European surveillance study showed wide variations in the rates of resistance across Europe, confirming the need to undertake susceptibility testing for individual isolates [135] and this has been replicated in other smaller series [135,136]. Looking at isolates from clinical specimens taken at shoulder surgery, Crane et al showed that rates of resistance to beta-lactams (such as penicillin, amoxicillin, cefazolin, ceftriaxone) remained very low [11,137]. However, they found slightly higher minimum inhibitory concentrations to vancomycin, and taking that information with the minimum biofilm eradication concentration from other studies [115,124], vancomycin may be less favorable than alternatives in the context of biofilm. This study also looked at quinolones (ciprofloxacin and moxifloxacin) but not levofloxacin, and showed high rates of susceptibility.

It is well recognized that the susceptibility of microorganisms is dramatically reduced in biofilms. For infections with staphylococci, there is good evidence for the use of rifampicin in combination therapy for its biofilm effect. The use of dual therapy with rifampicin for *C acnes* infections is theoretically attractive, although there is controversy in the literature. Bayston et al [128] found that linezolid plus rifampicin led to relapse-free eradication after 14 days compared to linezolid alone. Interestingly, in this study, penicillin alone was as effective as linezolid + rifampicin, but the effect of rifampicin + penicillin was not examined. Furustrand Tafin et al [124] in 2012 used an experimental foreign-body infection model to determine minimum inhibitory concentration and minimum biofilm eradication concentration with and without rifampicin for *C acnes* from cage fluid and from explanted cages. There was good activity of all antimicrobials tested for the planktonic forms, but rifampicin was needed for activity in the biofilm. They used an in vivo animal model to evaluate susceptibility to levofloxacin, vancomycin, daptomycin, and rifampicin; the highest cure rate was found with daptomycin and rifampicin (63%) followed by 46% for vancomycin and rifampicin combination. Emergence of

rifampicin resistance associated with the presence of the *rpoB* gene has however been shown to occur in vitro [138].

Combination therapy for *C acnes* has been further examined in vitro by Khassebaf et al [135] who took *C acnes* isolated from orthopedic implant infections and carried out susceptibility testing in addition to looking for synergistic, additive, and antagonistic effects of combinations. None of the antimicrobials examined were synergistic with each other and antagonistic effects were rare. Interestingly, the combination of rifampicin + benzylpenicillin showed an additive effect on almost 50% of isolates tested. However, a retrospective cohort study by Jacobs et al [125] showed no significant difference in success after 2 years between groups treated with combination antimicrobial treatment including rifampicin (88%) or not including rifampicin (82%). The most used antimicrobial in combination with rifampicin was clindamycin.

The performance of these antimicrobials in clinical studies is not easy to assess and there are very few published good quality studies with no prospective studies identified and limited utility of retrospective studies. Over a decade ago, Zeller et al [118] conducted a retrospective cohort study of 50 patients with *C acnes* PJI. Treatment involved surgery with antibiotics for the majority of patients. Intravenous therapy with cefazolin and rifampicin was administered to 24 of 50 patients and clindamycin with rifampicin to 11 cases for a duration of 5 ± 2 weeks followed by oral step down for a further 16 ± 8 weeks. Oral regimens were similar to the intravenous regimes: cephalexin + rifampicin or clindamycin + rifampicin [118,139].

Rienmüller's retrospective review of a tertiary infection center database included 24 cases of *C acnes* PJI over 14 years [140]. The strength of this study, despite being retrospective, was the use of contemporaneous clinical diagnosis of infection alongside the microbiological diagnosis. All patients underwent surgery and were treated with antibiotics but the specifics of antimicrobial treatment are not given, other than stating that they followed recommendations by Zimmerli et al [68] and were guided by the specific antibiogram. Lutz et al [116] report 52 cases over 7 years but differences in outcome between antimicrobial regimes were not given.

In summary, there are no randomized controlled trials or formally conducted comparative studies of specific antibiotic combinations for the treatment of *C acnes* PJI. Publications are confounded by difficulties and variations in definitions of infection, likely mixing true infections with contaminated cases. Surveillance studies suggest that *C acnes* remains highly susceptible to beta-lactams which are attractive from an antimicrobial stewardship point of view and are commonly used and recommended in Infectious Diseases Society of America guidelines [12,68,125,127–129,141]. Increasing rates of resistance for clindamycin and doxycycline are seen and antimicrobial therapy must therefore be based on the susceptibility testing of infecting pathogens determined using accredited methods; additive or synergistic testing might be helpful but the utility of this needs corroboration in clinical studies. Determining an appropriate targeted regimen at this stage can only be based on in vitro susceptibilities, on knowledge of oral bioavailability and bone penetration, and on an individual risk/benefit assessment for the use of rifampicin and other agents. Both the best oral antimicrobial and the role of rifampicin as part of combination therapy remain unclear, and well-conducted prospective randomized controlled trial studies are needed to help answer these questions.

Question 5: What antibiotic therapy and duration should be used in SSI/PJI caused by *Mycobacterium tuberculosis*?

Recommendation:

***Mycobacterium tuberculosis* (TB) periprosthetic joint infection (PJI) must be treated in collaboration with an infectious diseases specialist noting that the duration of treatment (minimum six months and up to two years) and the type of antimicrobials (usually a combination of four drugs) is determined based on the resistance profile of the pathogen.**

Level of Evidence: Limited

Delegate Vote: Agree: 96%, Disagree: 1%, Abstain: 3% (Unanimous, Strongest Consensus)

Rationale:

The review of the available literature on periprosthetic joint infection (PJI) caused by *Mycobacterium tuberculosis* (TB) is mainly based on retrospective cohort studies and case reports. Our exhaustive search of the literature revealed a total of 44 publications reporting on 62 patients with PJI caused by TB, over a period of 40 years [142–160][161–185].

Eight of the studies did not report on the type of antibiotic treatment utilized [142–149]. In other studies, reporting on the antimicrobial treatment, 3 patients were treated using a 2-drug combination regimen [150] and 23 patients received a 3 or 4-drug therapy [151–173]. Four patients were treated with more than 4 drugs [174–177]. Regarding the length of treatment [178], it was 6-9 months in 10 patients [179], 9-18 months in 21, and more than 18 months in 19 patients [180]. Based on the literature, only 3 patients had less than 6 months of antimicrobial therapy [181], but this may relate to the fact that 2 patients died during treatment.

The date related to surgical treatment was also evaluated. Eleven patients underwent debridement and retention of the prosthesis [182], 38 had resection arthroplasty and reimplantation [183], while 13 patients had no surgical treatment [184].

Due to the scarcity of the data related to PJI caused by *M tuberculosis*, we are unable to draw definitive recommendation for the antimicrobial treatment of surgical treatment for that matter. However, based on the recommendations of World Health Organization [185] for treatment of osteomyelitis caused by drug-susceptible TB, we feel that the 4-drug regimen (H, R, P, E) for 2 months followed by a 2-drug regimen (H, R) for a total treatment duration of 6-9 months (ie, 4-7 months, 2 drugs) may be the most optimal management of PJI caused by drug-susceptible *M tuberculosis*.

Question 6: Which antifungal agents are heat stable and what dose of these agents should be used in cement spacers for fungal PJI?

Recommendation:

Amphotericin B, preferably the liposomal formulation, and voriconazole are heat stable antifungal agents that are available in powder form and can be added to PMMA cement for spacers during treatment of patients with fungal PJI. The optimal dose of the antifungals that need to be added to a spacer is not known. However, in the literature the dose of amphotericin B ranges from 150 to 1500 mg per 40 g cement and the dose of voriconazole ranges from 200 to 1000 mg per 40 g cement. Antibiotics combined with antifungals should be considered for treatment/prevention of coexisting fungal and bacterial infection.

Level of Evidence: Consensus

Delegate Vote: Agree: 92%, Disagree: 2%, Abstain: 6% (Super Majority, Strong Consensus)

Rationale:

Fungi are known to form biofilms on implant and tissue surfaces with associated tolerance to antifungal agents. Data on the antifungal concentrations needed to achieve the minimum biofilm eradication concentration (MBEC) are limited. Parenteral/systemic administration of antifungals can achieve minimum inhibitory concentration but not MBEC, which is 10s-100s of times higher than the minimum inhibitory concentration for most antifungal-pathogen pairs. Local delivery is therefore required for most cases because it is expected that at a minimum, some biofilm fragments

Table 1
Summary of Literature Pertaining to the Use of Antifungal-Loaded Cement Spacers.

Year	Lead Author	Antifungal	Dose (mg/40 g Cement)	Study Design	Follow-Up (mo)	# Infection Free (%)	Organism
2018	Burgo [198]	Voriconazole and vancomycin	Not reported	Case report	24	1 (100%)	*Trichosporon inkin*
2017	Daniele [199]	Voriconazole	V-200	Case report	0	0 (0%)	*Scedosporium inflatum*
2016	Geng [197]	Amphotericin B ± vancomycin ± meropenem	A-200	8 patients retrospective review	35-78	7 (87.5%)	6 *Candida* species, 1 *Aspergillus*, 1 mold
2015	Wang [200]	Amphotericin B	A-100	5 patients retrospective review	46	5 (100%)	*Candida* species in 4 cases and *Pichia anomala* in 1 case
2015	Ong [201]	Amphotericin B	A-150	Case report	24	1 (100%)	*Arthrographis kalrae*
2015	MacLean [202]	Amphotericin B	A-1500	Case report	24	1 (100%)	Blastomycosis
2014	Skedros [203]	Amphotericin B	A-500	Case report	12	0 (0%)	*Candida glabrata* and *Serratia marcescens*
2013	Reddy [204]	Amphotericin B	Not reported	Case report	24	1 (100%)	*Candida tropicalis*
2013	Deelstra [205]	Amphotericin B and voriconazole	A-250 V-1000	Case report	72	1 (100%)	*Candida albicans*
2013	Ueng [206]	Amphotericin B ± vancomycin	Not reported	16 patients retrospective review	41	8 (50%)	9 *C albicans*, 6 *Candida parapsilosis*, 1 *C tropicalis*
2012	Hwang [207]	None Spacers had 2 g vancomycin/ batch no antifungal	Systemic	30 patients retrospective review	52	28 (93%)	24 were *Candida* species
2012	Hall [208]	Amphotericin B	A-150	Case report	24	1 (100%)	*Aspergillus*
2012	Denes [209]	Voriconazole	V-300	Case report	Not reported	Not reported	*C glabrata*
2011	Wu and Hsu [210]	Amphotericin B	A-1200	Case report	12	1 (100%)	*C albicans*
2011	Gottesman-Yekutieli [211]	Itraconazole	I-250	Case report	24	1 (100%)	Pseudallescheria *boydii*
2009	Wilkins [212]	Amphotericin B	Not reported	Case report	36	1 (100%)	*Rhizopus*
2009	Azzam [86]	Amphotericin B in 5 of 29 spacers	Not reported	29 patients retrospective review	45	9/19 (47%) reimplants	20 *C albicans*, 4 *C parapsilosis*, 3 *C albicans* + *C parapsilosis*, 3 non-*Candida* species
2004	Gaston and Ogden [213]	Amphotericin B + vancomycin	Not reported	Case report	9	0 (0%)	*C glabrata* amputation
2002	Phelan [214]	Fluconazole	F-200	4 patients retrospective review	60.5	1 (25%)	*Candida*
2001	Marra [215]	Amphotericin B	A-187.5	Case report	Not reported	0 (0%)	*C albicans*

remain in the wound following debridement. The local delivery vehicle that is most commonly used is polymethylmethacrylate (PMMA) formed into a spacer. To incorporate sufficient antimicrobials for the required local release, the antimicrobial must be in powder form because sufficiently high concentrations are not currently available in solution form. Echinocandin antifungals (ie, caspofungin and micafungin) are available in powder form and are water soluble [186], but their heat stability is not established and there are limited data on release from PMMA [187]. 5-Flucytosine is also available in powder form, but 5-flucytosine does not retain its bioactivity when incorporated into PMMA [188]. Amphotericin B and voriconazole are available in powder form [189–191]. Amphotericin B is heat stable and voriconazole has limited heat degradation over the polymerization time for PMMA [192–194]. Both have release data available and are active when eluted from antifungal-loaded bone cement [87,88,191]. However, both amphotericin B and voriconazole are not water soluble [195,196]. Amphotericin B is formulated with deoxycholate as a solubilizing agent. Liposomal formulations are also available in powder form and act to increase the release of amphotericin B from PMMA by an order of magnitude greater than amphotericin B deoxycholate. In total, 800 mg of liposomal amphotericin B (AmBisome) per 40 g of cement has been found to maximize amphotericin B release and not cause excessive mechanical weakness [87]. Toxicity studies are reported with cell injury in vitro, but no tissue injury in vivo at concentrations as high as 1000 μg/mL [86]. Voriconazole is formulated with cyclodextrin as a solubilizing agent [197]. The cyclodextrin powder is 16× the mass of voriconazole, resulting in a large enough powder volume to cause weakening of the cement [88]. In total, 300 mg of voriconazole per 40 g of cement leads to high levels of release, but also weakens compressive strength below the 70 MPa ISO 5833 standard for normal implant fixation. When the dose is increased to 600 mg per 40 g of cement, there is further weakening of compressive strength to about 20 MPa after elution [88]. For spacer fabrication, some level of attention needs to be paid to structural integrity, and the use of metal reinforcement within the cement may help to minimize the risk of spacer fracture.

Currently, there are limited data on the local tissue levels needed, the duration of MBEC exposure required, and the elution characteristics necessary to eradicate fungi from biofilm fragments. Clinical judgment must be used when choosing and dosing antifungal agents. The culture sensitivity in addition to the potential for antifungal toxicity must be weighed with the patient's medical history. Case reports and retrospective case series are valuable to consider in conjunction with the elution and mechanical data, and the clinical factors specific to individual cases when dosing decisions are being made. Thorough debridement remains the foundation of PJI management, including fungal PJI. High-quality prospective clinical trials will be needed to determine clinical outcomes when local tissue level targets and thorough debridement are achieved.

Studies and case reports on the use of antifungal-loaded bone cement spacers are provided in Table 1. In these reports, amphotericin B and voriconazole were the dominant antifungals used in spacers with the dose of amphotericin B ranging from 150 to 1500 mg per 40 g cement and the dose of voriconazole ranging from 200 to 1000 mg per 40 g cement. Most report clinical success when used in conjunction with thorough debridement and systemic antifungals; however, there are reports of acceptable outcomes even when antifungals were not used in any or all of the spacers [198,199,207].

References

[1] Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin Orthop Relat Res 2008;466:1710–5. https://doi.org/10.1007/s11999-008-0209-4.

[2] Holleyman RJ, Baker PN, Charlett A, Gould K, Deehan DJ. Microorganisms responsible for periprosthetic knee infections in England and Wales. Knee Surg Sports Traumatol Arthrosc 2016;24:3080–7.

[3] Moran E, Masters S, Berendt AR, McLardy-Smith P, Byren I, Atkins BL. Guiding empirical antibiotic therapy in orthopaedics: the microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect 2007;55:1–7. https://doi.org/10.1016/j.jinf.2007.01.007.

[4] Peel TN, Cheng AC, Buising KL, Choong PFM. Microbiological aetiology, epidemiology, and clinical profile of prosthetic joint infections: are current antibiotic prophylaxis guidelines effective? Antimicrob Agents Chemother 2012;56:2386–91. https://doi.org/10.1128/AAC.06246-11.

[5] Tan TL, Kheir MM, Tan DD, Parvizi J. Polymicrobial periprosthetic joint infections: outcome of treatment and identification of risk factors. J Bone Joint Surg Am 2016;98:2082–8. https://doi.org/10.2106/JBJS.15.01450.

[6] Wimmer MD, Friedrich MJ, Randau TM, Ploeger MM, Schmolders J, Strauss AA, et al. Polymicrobial infections reduce the cure rate in prosthetic joint infections: outcome analysis with two-stage exchange and follow-up ≥two years. Int Orthop 2016;40:1367–73. https://doi.org/10.1007/s00264-015-2871-y.

[7] Marculescu CE, Cantey JR. Polymicrobial prosthetic joint infections: risk factors and outcome. Clin Orthop Relat Res 2008;466:1397–404. https://doi.org/10.1007/s11999-008-0230-7.

[8] Bozhkova S, Tikhilov R, Labutin D, Denisov A, Shubnyakov I, Razorenov V, et al. Failure of the first step of two-stage revision due to polymicrobial prosthetic joint infection of the hip. J Orthop Traumatol 2016;17:369–76. https://doi.org/10.1007/s10195-016-0417-8.

[9] Figa R, Muñetón D, Gómez L, Matamala A, Lung M, Cuchi E, et al. Periprosthetic joint infection by *Propionibacterium acnes*: clinical differences between monomicrobial versus polymicrobial infection. Anaerobe 2017;44:143–9. https://doi.org/10.1016/j.anaerobe.2017.03.008.

[10] Zmistowski B, Fedorka CJ, Sheehan E, Deirmengian G, Austin MS, Parvizi J. Prosthetic joint infection caused by gram-negative organisms. J Arthroplasty 2011;26:104–8. https://doi.org/10.1016/j.arth.2011.03.044.

[11] Kheir MM, Tan TL, Higuera C, George J, Della Valle CJ, Shen M, et al. Periprosthetic joint infections caused by enterococci have poor outcomes. J Arthroplasty 2017;32:933–47. https://doi.org/10.1016/j.arth.2016.09.017.

[12] Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013;56:e1–25. https://doi.org/10.1093/cid/cis803.

[13] Sousa R, Pereira A, Massada M, da Silva MV, Lemos R, Costa e Castro J. Empirical antibiotic therapy in prosthetic joint infections. Acta Orthop Belg 2010;76:254–9.

[14] Frank JM, Kayupov E, Moric M, Segreti J, Hansen E, Hartman C, et al. The Mark Coventry, MD, Award: oral antibiotics reduce reinfection after two-stage exchange: a multicenter, randomized controlled trial. Clin Orthop Relat Res 2017;475:56–61. https://doi.org/10.1007/s11999-016-4890-4.

[15] Siqueira MBP, Saleh A, Klika AK, O'Rourke C, Schmitt S, Higuera CA, et al. Chronic suppression of periprosthetic joint infections with oral antibiotics increases infection-free survivorship. J Bone Joint Surg Am 2015;97:1220–32. https://doi.org/10.2106/JBJS.N.00999.

[16] Tzeng A, Tzeng TH, Vasdev S, Korth K, Healey T, Parvizi J, et al. Treating periprosthetic joint infections as biofilms: key diagnosis and management strategies. Diagn Microbiol Infect Dis 2015;81:192–200. https://doi.org/10.1016/j.diagmicrobio.2014.08.018.

[17] Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sørensen SR, Moser C, Kühl M, et al. The in vivo biofilm. Trends Microbiol 2013;21:466–74. https://doi.org/10.1016/j.tim.2013.06.002.

[18] Sendi P, Zimmerli W. Antimicrobial treatment concepts for orthopaedic device-related infection. Clin Microbiol Infect 2012;18:1176–84. https://doi.org/10.1111/1469-0691.12003.

[19] Bradbury T, Fehring TK, Taunton M, Hanssen A, Azzam K, Parvizi J, et al. The fate of acute methicillin-resistant *Staphylococcus aureus* periprosthetic knee infections treated by open debridement and retention of components. J Arthroplasty 2009;24:101–4. https://doi.org/10.1016/j.arth.2009.04.028.

[20] Garrigós C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, et al. Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant *Staphylococcus aureus*. Antimicrob Agents Chemother 2012;56:3806–11. https://doi.org/10.1128/AAC.00127-12.

[21] El Haj C, Murillo O, Ribera A, Vivas M, Garcia-Somoza D, Tubau F, et al. Comparative efficacies of cloxacillin-daptomycin and the standard cloxacillin-rifampin therapies against an experimental foreign-body infection by methicillin-susceptible *Staphylococcus aureus*. Antimicrob Agents Chemother 2014;58:5576–80. https://doi.org/10.1128/AAC.02681-14.

[22] Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, et al. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant *Staphylococcus aureus* strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 2012;56:6192–200. https://doi.org/10.1128/AAC.01525-12.

[23] Schwank S, Rajacic Z, Zimmerli W, Blaser J. Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrob Agents Chemother 1998;42:895–8.

[24] Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279:1537–41.

[25] Chuard C, Herrmann M, Vaudaux P, Waldvogel FA, Lew DP. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant *Staphylococcus aureus* by antimicrobial combinations. Antimicrob Agents Chemother 1991;35:2611–6.

[26] Lora-Tamayo J, Murillo O, Iribarren JA, Soriano A, Sánchez-Somolinos M, Baraia-Etxaburu JM, et al. A large multicenter study of methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* prosthetic joint infections managed with implant retention. Clin Infect Dis 2013;56:182–94. https://doi.org/10.1093/cid/cis746.

[27] Senneville E, Joulie D, Legout L, Valette M, Dezèque H, Beltrand E, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to *Staphylococcus aureus*. Clin Infect Dis 2011;53:334–40. https://doi.org/10.1093/cid/cir402.

[28] El Helou OC, Berbari EF, Lahr BD, Eckel-Passow JE, Razonable RR, Sia IG, et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010;29:961–7. https://doi.org/10.1007/s10096-010-0952-9.

[29] Drancourt M, Stein A, Argenson JN, Zannier A, Curvale G, Raoult D. Oral rifampin plus ofloxacin for treatment of *Staphylococcus*-infected orthopedic implants. Antimicrob Agents Chemother 1993;37:1214–8.

[30] Marschall J, Lane MA, Beekmann SE, Polgreen PM, Babcock HM. Current management of prosthetic joint infections in adults: results of an Emerging Infections Network survey. Int J Antimicrob Agents 2013;41:272–7. https://doi.org/10.1016/j.ijantimicag.2012.10.023.

[31] Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate *Staphylococcus aureus* (VISA), vancomycin-susceptible clinical methicillin-resistant *S. aureus* (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007;60:788–94. https://doi.org/10.1093/jac/dkm258.

[32] Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for *Staphylococcus aureus* clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44:3883–6. https://doi.org/10.1128/JCM.01388-06.

[33] Tang H-J, Chen C-C, Ko W-C, Yu W-L, Chiang S-R, Chuang Y-C. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded methicillin-resistant *Staphylococcus aureus* with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA). Int J Antimicrob Agents 2011;38:46–51. https://doi.org/10.1016/j.ijantimicag.2011.02.013.

[34] Tang H-J, Chen C-C, Cheng K-C, Wu K-Y, Lin Y-C, Zhang C-C, et al. In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant *Staphylococcus aureus*. Antimicrob Agents Chemother 2013;57:5717–20. https://doi.org/10.1128/AAC.01236-13.

[35] El Haj C, Murillo O, Ribera A, Vivas M, Garcia-Somoza D, Tubau F, et al. Daptomycin combinations as alternative therapies in experimental foreign-body infection caused by methicillin-susceptible *Staphylococcus aureus*. Int J Antimicrob Agents 2015;46:189–95. https://doi.org/10.1016/j.ijantimicag.2015.04.004.

[36] Saleh-Mghir A, Muller-Serieys C, Dinh A, Massias L, Crémieux A-C. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant *Staphylococcus aureus*. Antimicrob Agents Chemother 2011;55:4589–93. https://doi.org/10.1128/AAC.00675-11.

[37] Garrigós C, Murillo O, Euba G, Verdaguer R, Tubau F, Cabellos C, et al. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant *Staphylococcus aureus*. Antimicrob Agents Chemother 2010;54:5251–6. https://doi.org/10.1128/AAC.00226-10.

[38] Garrigós C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, et al. Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant *Staphylococcus aureus*. Antimicrob Agents Chemother 2013;57:606–10. https://doi.org/10.1128/AAC.01570-12.

[39] John A-K, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant *Staphylococcus aureus*: importance of combination with rifampin. Antimicrob Agents Chemother 2009;53:2719–24. https://doi.org/10.1128/AAC.00047-09.

[40] Chang Y-J, Lee MS, Lee C-H, Lin P-C, Kuo F-C. Daptomycin treatment in patients with resistant staphylococcal periprosthetic joint infection. BMC Infect Dis 2017;17:736. https://doi.org/10.1186/s12879-017-2842-6.

[41] Kuo F-C, Yen S-H, Peng K-T, Wang J-W, Lee MS. Methicillin-resistant staphylococcal periprosthetic joint infections can be effectively controlled by systemic and local daptomycin. BMC Infect Dis 2016;16:48. https://doi.org/10.1186/s12879-016-1366-9.

[42] Rao N, Regalla DM. Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin Orthop Relat Res 2006;451:34–7. https://doi.org/10.1097/01.blo.0000224021.73163.61.
[43] Lora-Tamayo J, Parra-Ruiz J, Rodríguez-Pardo D, Barberán J, Ribera A, Tornero E, et al. High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study. Diagn Microbiol Infect Dis 2014;80:66–71. https://doi.org/10.1016/j.diagmicrobio.2014.05.022.
[44] Gatin L, Saleh-Mghir A, Tasse J, Ghout I, Laurent F, Crémieux A-C. Ceftaroline-Fosamil efficacy against methicillin-resistant *Staphylococcus aureus* in a rabbit prosthetic joint infection model. Antimicrob Agents Chemother 2014;58:6496–500. https://doi.org/10.1128/AAC.03600-14.
[45] Barber KE, Smith JR, Ireland CE, Boles BR, Rose WE, Rybak MJ. Evaluation of ceftaroline alone and in combination against biofilm-producing methicillin-resistant *Staphylococcus aureus* with reduced susceptibility to daptomycin and vancomycin in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2015;59:4497–503. https://doi.org/10.1128/AAC.00386-15.
[46] Garrigós C, Murillo O, Euba G, Verdaguer R, Tubau F, Cabellos C, et al. Efficacy of tigecycline alone and with rifampin in foreign-body infection by methicillin-resistant *Staphylococcus aureus*. J Infect 2011;63:229–35. https://doi.org/10.1016/j.jinf.2011.07.001.
[47] Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009;34:8.e1–9. https://doi.org/10.1016/j.ijantimicag.2008.11.006.
[48] Vouillamoz J, Moreillon P, Giddey M, Entenza JM. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens. J Antimicrob Chemother 2008;61:371–4. https://doi.org/10.1093/jac/dkm459.
[49] Thompson JM, Saini V, Ashbaugh AG, Miller RJ, Ordonez AA, Ortines RV, et al. Oral-only linezolid-rifampin is highly effective compared with other antibiotics for periprosthetic joint infection: study of a mouse model. J Bone Joint Surg Am 2017;99:656–65. https://doi.org/10.2106/JBJS.16.01002.
[50] Wu W-S, Chen C-C, Chuang Y-C, Su B-A, Chiu Y-H, Hsu H-J, et al. Efficacy of combination oral antimicrobial agents against biofilm-embedded methicillin-resistant *Staphylococcus aureus*. J Microbiol Immunol Infect 2013;46:89–95. https://doi.org/10.1016/j.jmii.2012.03.009.
[51] Murillo O, Domenech A, Euba G, Verdaguer R, Tubau F, Cabo J, et al. Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J Infect 2008;57:229–35. https://doi.org/10.1016/j.jinf.2008.07.003.
[52] Gómez J, Canovas E, Baños V, Martínez L, García E, Hernández-Torres A, et al. Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant. Antimicrob Agents Chemother 2011;55:4308–10. https://doi.org/10.1128/AAC.00352-11.
[53] Morata L, Senneville E, Bernard L, Nguyen S, Buzelé R, Druon J, et al. A retrospective review of the clinical experience of linezolid with or without rifampicin in prosthetic joint infections treated with debridement and implant retention. Infect Dis Ther 2014;3:235–43. https://doi.org/10.1007/s40121-014-0032-z.
[54] Legout L, Valette M, Dezeque H, Nguyen S, Lemaire X, Loïez C, et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? J Antimicrob Chemother 2010;65:2224–30. https://doi.org/10.1093/jac/dkq281.
[55] Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, Obach RS, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2011;51:229–36. https://doi.org/10.1177/0091270010366445.
[56] Nguyen S, Pasquet A, Legout L, Beltrand E, Dubreuil L, Migaud H, et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009;15:1163–9. https://doi.org/10.1111/j.1469-0691.2009.02761.x.
[57] Stein A, Bataille JF, Drancourt M, Curvale G, Argenson JN, Groulier P, et al. Ambulatory treatment of multidrug-resistant *Staphylococcus*-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998;42:3086–91.
[58] Achermann Y, Eigenmann K, Ledergerber B, Derksen L, Rafeiner P, Clauss M, et al. Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case–control study. Infection 2013;41:431–7. https://doi.org/10.1007/s15010-012-0325-7.
[59] Tang H-J, Chen C-C, Cheng K-C, Toh H-S, Su B-A, Chiang S-R, et al. In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant *Staphylococcus aureus* in biofilms. J Antimicrob Chemother 2012;67:944–50. https://doi.org/10.1093/jac/dkr535.
[60] Brinkman CL, Schmidt-Malan SM, Mandrekar JN, Patel R. Rifampin-based combination therapy is active in foreign-body osteomyelitis after prior rifampin monotherapy. Antimicrob Agents Chemother 2017;61. https://doi.org/10.1128/AAC.01822-16.
[61] Parra-Ruiz J, Bravo-Molina A, Peña-Monje A, Hernández-Quero J. Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of *Staphylococcus aureus* biofilm. J Antimicrob Chemother 2012;67:2682–5. https://doi.org/10.1093/jac/dks272.
[62] Soriano A, Gómez J, Gómez L, Azanza JR, Pérez R, Romero F, et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis 2007;26:353–6. https://doi.org/10.1007/s10096-007-0289-1.
[63] Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007;59:173–9. https://doi.org/10.1016/j.diagmicrobio.2007.04.006.
[64] Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004;79:1137–44. https://doi.org/10.4065/79.9.1137.
[65] Pushkin R, Iglesias-Ussel MD, Keedy K, MacLauchlin C, Mould DR, Berkowitz R, et al. A randomized study evaluating oral fusidic acid (CEM-102) in combination with oral rifampin compared with standard-of-care antibiotics for treatment of prosthetic joint infections: a newly identified drug-drug interaction. Clin Infect Dis 2016;63:1599–604. https://doi.org/10.1093/cid/ciw665.
[66] Marsot A, Ménard A, Dupouey J, Muziotti C, Guilhaumou R, Blin O. Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. Br J Clin Pharmacol 2017;83:1039–47. https://doi.org/10.1111/bcp.13178.
[67] Curis E, Pestre V, Jullien V, Eyrolle L, Archambeau D, Morand P, et al. Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. Infection 2015;43:473–81. https://doi.org/10.1007/s15010-015-0773-y.
[68] Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004;351:1645–54. https://doi.org/10.1056/NEJMra040181.
[69] Furustrand Tafin U, Majic I, Zalila Belkhodja C, Betrisey B, Corvec S, Zimmerli W, et al. Gentamicin improves the activities of daptomycin and vancomycin against *Enterococcus faecalis* in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother 2011;55:4821–7. https://doi.org/10.1128/AAC.00141-11.
[70] Hsieh P-H, Lee MS, Hsu K-Y, Chang Y-H, Shih H-N, Ueng SW. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis 2009;49:1036–43. https://doi.org/10.1086/605593.
[71] Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev 2014;27:302–45. https://doi.org/10.1128/CMR.00111-13.
[72] Widmer AF, Wiestner A, Frei R, Zimmerli W. Killing of nongrowing and adherent *Escherichia coli* determines drug efficacy in device-related infections. Antimicrob Agents Chemother 1991;35:741–6.
[73] Aboltins CA, Dowsey MM, Buising KL, Peel TN, Daffy JR, Choong PFM, et al. Gram-negative prosthetic joint infection treated with debridement, prosthesis retention and antibiotic regimens including a fluoroquinolone. Clin Microbiol Infect 2011;17:862–7. https://doi.org/10.1111/j.1469-0691.2010.03361.x.
[74] Legout L, Senneville E, Stern R, Yazdanpanah Y, Savage C, Roussel-Delvalez M, et al. Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination. Clin Microbiol Infect 2006;12:1030–3. https://doi.org/10.1111/j.1469-0691.2006.01523.x.
[75] Brouqui P, Rousseau MC, Stein A, Drancourt M, Raoult D. Treatment of *Pseudomonas aeruginosa*-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Antimicrob Agents Chemother 1995;39:2423–5.
[76] Rodríguez-Pardo D, Pigrau C, Lora-Tamayo J, Soriano A, del Toro MD, Cobo J, et al. Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. Clin Microbiol Infect 2014;20:O911–9. https://doi.org/10.1111/1469-0691.12649.
[77] de Sanctis J, Teixeira L, van Duin D, Odio C, Hall G, Tomford JW, et al. Complex prosthetic joint infections due to carbapenemase-producing *Klebsiella pneumoniae*: a unique challenge in the era of untreatable infections. Int J Infect Dis 2014;25:73–8. https://doi.org/10.1016/j.ijid.2014.01.028.
[78] Michail G, Labrou M, Pitiriga V, Manousaka S, Sakellaridis N, Tsakris A, et al. Activity of tigecycline in combination with colistin, meropenem, rifampin, or gentamicin against KPC-producing enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother 2013;57:6028–33. https://doi.org/10.1128/AAC.00891-13.
[79] Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing *Escherichia coli* in a foreign-body infection model. Antimicrob Agents Chemother 2013;57:1421–7. https://doi.org/10.1128/AAC.01718-12.
[80] Drago L, De Vecchi E, Nicola L, Tocalli L, Gismondo MR. In vitro selection of resistance in *Pseudomonas aeruginosa* and *Acinetobacter* spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. J Antimicrob Chemother 2005;56:353–9. https://doi.org/10.1093/jac/dki204.
[81] Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of *Pseudomonas aeruginosa* infections. Clin Infect Dis 2005;40(Suppl. 2):S99–104. https://doi.org/10.1086/426189.
[82] Ribera A, Benavent E, Lora-Tamayo J, Tubau F, Pedrero S, Cabo X, et al. Osteoarticular infection caused by MDR *Pseudomonas aeruginosa*: the benefits of combination therapy with colistin plus β-lactams. J Antimicrob Chemother 2015;70:3357–65. https://doi.org/10.1093/jac/dkv281.
[83] Lora-Tamayo J, Murillo O, Bergen PJ, Nation RL, Poudyal A, Luo X, et al. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant *Pseudomonas aeruginosa* in an in vitro dynamic biofilm model. J Antimicrob Chemother 2014;69:2434–42. https://doi.org/10.1093/jac/dku151.

[84] Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2015;46:266–71. https://doi.org/10.1016/j.ijantimicag.2015.05.003.
[85] Brown TS, Petis SM, Osmon DR, Mabry TM, Berry DJ, Hanssen AD, et al. Periprosthetic joint infection with fungal pathogens. J Arthroplasty 2018;33:2605–12. https://doi.org/10.1016/j.arth.2018.03.003.
[86] Azzam K, Parvizi J, Jungkind D, Hanssen A, Fehring T, Springer B, et al. Microbiological, clinical, and surgical features of fungal prosthetic joint infections: a multi-institutional experience. J Bone Joint Surg Am 2009;91(Suppl. 6):142–9. https://doi.org/10.2106/JBJS.I.00574.
[87] Cunningham B, McLaren AC, Pauken C, McLemore R. Liposomal formulation increases local delivery of amphotericin from bone cement: a pilot study. Clin Orthop Relat Res 2012;470:2671–6. https://doi.org/10.1007/s11999-012-2317-4.
[88] Miller RB, McLaren AC, Pauken C, Clarke HD, McLemore R. Voriconazole is delivered from antifungal-loaded bone cement. Clin Orthop Relat Res 2013;471:195–200. https://doi.org/10.1007/s11999-012-2463-8.
[89] Levy PY, Fenollar F, Stein A, Borrione F, Cohen E, Lebail B, et al. Propionibacterium acnes postoperative shoulder arthritis: an emerging clinical entity. Clin Infect Dis 2008;46:1884–6. https://doi.org/10.1086/588477.
[90] Dodson CC, Craig EV, Cordasco FA, Dines DM, Dines JS, Dicarlo E, et al. *Propionibacterium acnes* infection after shoulder arthroplasty: a diagnostic challenge. J Shoulder Elbow Surg 2010;19:303–7. https://doi.org/10.1016/j.jse.2009.07.065.
[91] Butler-Wu SM, Burns EM, Pottinger PS, Magaret AS, Rakeman JL, Matsen FA, et al. Optimization of periprosthetic culture for diagnosis of *Propionibacterium acnes* prosthetic joint infection. J Clin Microbiol 2011;49:2490–5. https://doi.org/10.1128/JCM.00450-11.
[92] Patel A, Calfee RP, Plante M, Fischer SA, Green A. *Propionibacterium acnes* colonization of the human shoulder. J Shoulder Elbow Surg 2009;18:897–902. https://doi.org/10.1016/j.jse.2009.01.023.
[93] Millett PJ, Yen Y-M, Price CS, Horan MP, van der Meijden OA, Elser F. *Propionibacterium acnes* infection as an occult cause of postoperative shoulder pain: a case series. Clin Orthop Relat Res 2011;469:2824–30. https://doi.org/10.1007/s11999-011-1767-4.
[94] Topolski MS, Chin PYK, Sperling JW, Cofield RH. Revision shoulder arthroplasty with positive intraoperative cultures: the value of preoperative studies and intraoperative histology. J Shoulder Elbow Surg 2006;15:402–6. https://doi.org/10.1016/j.jse.2005.10.001.
[95] Bjerke-Kroll BT, Christ AB, McLawhorn AS, Sculco PK, Jules-Elysée KM, Sculco TP. Periprosthetic joint infections treated with two-stage revision over 14 years: an evolving microbiology profile. J Arthroplasty 2014;29:877–82. https://doi.org/10.1016/j.arth.2013.09.053.
[96] Nodzo SR, Westrich GH, Henry MW, Miller AO. Clinical analysis of *Propionibacterium acnes* infection after total knee arthroplasty. J Arthroplasty 2016;31:1986–9. https://doi.org/10.1016/j.arth.2016.02.025.
[97] Bémer P, Corvec S, Tariel S, Asseray N, Boutoille D, Langlois C, et al. Significance of *Propionibacterium acnes*-positive samples in spinal instrumentation. Spine 2008;33:E971–6. https://doi.org/10.1097/BRS.0b013e31818e28dc.
[98] Richards BR, Emara KM. Delayed infections after posterior TSRH spinal instrumentation for idiopathic scoliosis: revisited. Spine 2001;26:1990–6.
[99] Viola RW, King HA, Adler SM, Wilson CB. Delayed infection after elective spinal instrumentation and fusion. A retrospective analysis of eight cases. Spine 1997;22:2444–50 [discussion 2450-2451].
[100] McLorinan GC, Glenn JV, McMullan MG, Patrick S. *Propionibacterium acnes* wound contamination at the time of spinal surgery. Clin Orthop Relat Res 2005;437:67–73.
[101] Nodzo SR, Boyle KK, Bhimani S, Duquin TR, Miller AO, Westrich GH. *Propionibacterium acnes* host inflammatory response during periprosthetic infection is joint specific. HSS J 2017;13:159–64. https://doi.org/10.1007/s11420-016-9528-2.
[102] Hudek R, Sommer F, Kerwat M, Abdelkawi AF, Loos F, Gohlke F. *Propionibacterium acnes* in shoulder surgery: true infection, contamination, or commensal of the deep tissue? J Shoulder Elbow Surg 2014;23:1763–71. https://doi.org/10.1016/j.jse.2014.05.024.
[103] Singh JA, Sperling JW, Schleck C, Harmsen WS, Cofield RH. Periprosthetic infections after total shoulder arthroplasty: a 33-year perspective. J Shoulder Elbow Surg 2012;21:1534–41. https://doi.org/10.1016/j.jse.2012.01.006.
[104] Tarabichi M, Shohat N, Goswami K, Alvand A, Silibovsky R, Belden K, et al. Diagnosis of periprosthetic joint infection: the potential of next-generation sequencing. J Bone Joint Surg Am 2018;100:147–54. https://doi.org/10.2106/JBJS.17.00434.
[105] Sampedro MF, Piper KE, McDowell A, Patrick S, Mandrekar JN, Rouse MS, et al. Species of *Propionibacterium* and *Propionibacterium acnes* phylotypes associated with orthopedic implants. Diagn Microbiol Infect Dis 2009;64:138–45. https://doi.org/10.1016/j.diagmicrobio.2009.01.024.
[106] Nodzo SR, Hohman DW, Crane JK, Duquin TR. Hemolysis as a clinical marker for *Propionibacterium acnes* orthopedic infection. Am J Orthop 2014;43:E93–7.
[107] Nakatsuji T, Tang DC, Zhang L, Gallo RL, Huang C-M. *Propionibacterium acnes* CAMP factor and host acid sphingomyelinase contribute to bacterial virulence: potential targets for inflammatory acne treatment. PLoS One 2011;6:e14797. https://doi.org/10.1371/journal.pone.0014797.
[108] Achermann Y, Goldstein EJC, Coenye T, Shirtliff ME. *Propionibacterium acnes*: from commensal to opportunistic biofilm-associated implant pathogen. Clin Microbiol Rev 2014;27:419–40. https://doi.org/10.1128/CMR.00092-13.
[109] Gristina AG, Naylor P, Myrvik Q. Infections from biomaterials and implants: a race for the surface. Med Prog Technol 1988;14:205–24.
[110] McDowell A, Valanne S, Ramage G, Tunney MM, Glenn JV, McLorinan GC, et al. *Propionibacterium acnes* types I and II represent phylogenetically distinct groups. J Clin Microbiol 2005;43:326–34. https://doi.org/10.1128/JCM.43.1.326-334.2005.
[111] Crane JK, Hohman DW, Nodzo SR, Duquin TR. Antimicrobial susceptibility of *Propionibacterium acnes* isolates from shoulder surgery. Antimicrob Agents Chemother 2013;57:3424–6. https://doi.org/10.1128/AAC.00463-13.
[112] Brook I. Pathogenicity of *Propionibacterium acnes* in mixed infections with facultative bacteria. J Med Microbiol 1991;34:249–52. https://doi.org/10.1099/00222615-34-5-249.
[113] Choudhury TK. Synergistic lysis of erythrocytes by *Propionibacterium acnes*. J Clin Microbiol 1978;8:238–41.
[114] Holmberg A, Lood R, Mörgelin M, Söderquist B, Holst E, Collin M, et al. Biofilm formation by *Propionibacterium acnes* is a characteristic of invasive isolates. Clin Microbiol Infect 2009;15:787–95. https://doi.org/10.1111/j.1469-0691.2009.02747.x.
[115] Ramage G, Tunney MM, Patrick S, Gorman SP, Nixon JR. Formation of *Propionibacterium acnes* biofilms on orthopaedic biomaterials and their susceptibility to antimicrobials. Biomaterials 2003;24:3221–7.
[116] Lutz M-F, Berthelot P, Fresard A, Cazorla C, Carricajo A, Vautrin A-C, et al. Arthroplastic and osteosynthetic infections due to *Propionibacterium acnes*: a retrospective study of 52 cases, 1995-2002. Eur J Clin Microbiol Infect Dis 2005;24:739–44. https://doi.org/10.1007/s10096-005-0040-8.
[117] Lavergne V, Malo M, Gaudelli C, Laprade M, Leduc S, Laflamme P, et al. Clinical impact of positive *Propionibacterium acnes* cultures in orthopedic surgery. Orthop Traumatol Surg Res 2017;103:307–14. https://doi.org/10.1016/j.otsr.2016.12.005.
[118] Zeller V, Ghorbani A, Strady C, Leonard P, Mamoudy P, Desplaces N. *Propionibacterium acnes*: an agent of prosthetic joint infection and colonization. J Infect 2007;55:119–24. https://doi.org/10.1016/j.jinf.2007.02.006.
[119] Jacquot A, Sirveaux F, Roche O, Favard L, Clavert P, Molé D. Surgical management of the infected reversed shoulder arthroplasty: a French multicenter study of reoperation in 32 patients. J Shoulder Elbow Surg 2015;24:1713–22. https://doi.org/10.1016/j.jse.2015.03.007.
[120] Gausden EB, Villa J, Warner SJ, Redko M, Pearle A, Miller A, et al. Nonunion after clavicle osteosynthesis: high incidence of *Propionibacterium acnes*. J Orthop Trauma 2017;31:229–35. https://doi.org/10.1097/BOT.0000000000000770.
[121] Piggott DA, Higgins YM, Melia MT, Ellis B, Carroll KC, McFarland EG, et al. Characteristics and treatment outcomes of *Propionibacterium acnes* prosthetic shoulder infections in adults. Open Forum Infect Dis 2016;3:ofv191. https://doi.org/10.1093/ofid/ofv191.
[122] Hahn F, Zbinden R, Min K. Late implant infections caused by *Propionibacterium acnes* in scoliosis surgery. Eur Spine J 2005;14:783–8. https://doi.org/10.1007/s00586-004-0854-6.
[123] Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, et al. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013;56:1–10. https://doi.org/10.1093/cid/cis966.
[124] Furustrand Tafin U, Corvec S, Betrisey B, Zimmerli W, Trampuz A. Role of rifampin against *Propionibacterium acnes* biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother 2012;56:1885–91. https://doi.org/10.1128/AAC.05552-11.
[125] Jacobs AME, Van Hooff ML, Meis JF, Vos F, Goosen JHM. Treatment of prosthetic joint infections due to *Propionibacterium*. Similar results in 60 patients treated with and without rifampicin. Acta Orthop 2016;87:60–6. https://doi.org/10.3109/17453674.2015.1094613.
[126] Levy O, Iyer S, Atoun E, Peter N, Hous N, Cash D, et al. *Propionibacterium acnes*: an underestimated etiology in the pathogenesis of osteoarthritis? J Shoulder Elbow Surg 2013;22:505–11. https://doi.org/10.1016/j.jse.2012.07.007.
[127] Boisrenoult P. *Cutibacterium acnes* prosthetic joint infection: diagnosis and treatment. Orthop Traumatol Surg Res 2018;104:S19–24. https://doi.org/10.1016/j.otsr.2017.05.030.
[128] Bayston R, Nuradeen B, Ashraf W, Freeman BJC. Antibiotics for the eradication of *Propionibacterium acnes* biofilms in surgical infection. J Antimicrob Chemother 2007;60:1298–301. https://doi.org/10.1093/jac/dkm408.
[129] Corvec S, Aubin GG, Bayston R, Ashraf W. Which is the best treatment for prosthetic joint infections due to *Propionibacterium acnes*: need for further biofilm in vitro and experimental foreign-body in vivo studies? Acta Orthop 2016;87:318–9. https://doi.org/10.3109/17453674.2016.1162037.
[130] Falconer TM, Baba M, Kruse LM, Dorrestijn O, Donaldson MJ, Smith MM, et al. Contamination of the surgical field with *Propionibacterium acnes* in primary shoulder arthroplasty. J Bone Joint Surg Am 2016;98:1722–8. https://doi.org/10.2106/JBJS.15.01133.
[131] Heckmann N, Sivasundaram L, Heidari KS, Weber AE, Mayer EN, Omid R, et al. *Propionibacterium acnes* persists despite various skin preparation

techniques. Arthroscopy 2018;34:1786–9. https://doi.org/10.1016/j.arthro.2018.01.019.
[132] Atkins BL, Athanasou N, Deeks JJ, Crook DW, Simpson H, Peto TE, et al. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty. The OSIRIS collaborative study group. J Clin Microbiol 1998;36:2932–9.
[133] Schwotzer N, Wahl P, Fracheboud D, Gautier E, Chuard C. Optimal culture incubation time in orthopedic device-associated infections: a retrospective analysis of prolonged 14-day incubation. J Clin Microbiol 2014;52:61–6. https://doi.org/10.1128/JCM.01766-13.
[134] Trampuz A, Piper KE, Jacobson MJ, Hanssen AD, Unni KK, Osmon DR, et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med 2007;357:654–63. https://doi.org/10.1056/NEJMoa061588.
[135] Khassebaf J, Hellmark B, Davidsson S, Unemo M, Nilsdotter-Augustinsson Å, Söderquist B. Antibiotic susceptibility of *Propionibacterium acnes* isolated from orthopaedic implant-associated infections. Anaerobe 2015;32:57–62. https://doi.org/10.1016/j.anaerobe.2014.12.006.
[136] Portillo ME, Corvec S, Borens O, Trampuz A. *Propionibacterium acnes*: an underestimated pathogen in implant-associated infections. Biomed Res Int 2013;2013:804391. https://doi.org/10.1155/2013/804391.
[137] Achermann Y, Sahin F, Schwyzer HK, Kolling C, Wüst J, Vogt M. Characteristics and outcome of 16 periprosthetic shoulder joint infections. Infection 2013;41:613–20. https://doi.org/10.1007/s15010-012-0360-4.
[138] Furustrand Tafin U, Aubin GG, Eich G, Trampuz A, Corvec S. Occurrence and new mutations involved in rifampicin-resistant *Propionibacterium acnes* strains isolated from biofilm or device-related infections. Anaerobe 2015;34:116–9. https://doi.org/10.1016/j.anaerobe.2015.05.003.
[139] Gharamti AA, Kanafani ZA. *Cutibacterium* (formerly *Propionibacterium*) *acnes* infections associated with implantable devices. Expert Rev Anti Infect Ther 2017;15:1083–94. https://doi.org/10.1080/14787210.2017.1404452.
[140] Rienmüller A, Borens O. *Propionibacterium* prosthetic joint infection: experience from a retrospective database analysis. Eur J Orthop Surg Traumatol 2016;26:429–34. https://doi.org/10.1007/s00590-016-1766-y.
[141] Aubin GG, Portillo ME, Trampuz A, Corvec S. *Propionibacterium acnes*, an emerging pathogen: from acne to implant-infections, from phylotype to resistance. Med Mal Infect 2014;44:241–50. https://doi.org/10.1016/j.medmal.2014.02.004.
[142] McCullough CJ. Tuberculosis as a late complication of total hip replacement. Acta Orthop Scand 1977;48:508–10.
[143] Hecht RH, Meyers MH, Thornhill-Joynes M, Montgomerie JZ. Reactivation of tuberculous infection following total joint replacement. A case report. J Bone Joint Surg Am 1983;65:1015–6.
[144] Zeiger LS, Watters W, Sherk H. Scintigraphic detection of prosthetic joint and soft tissue sepsis secondary to tuberculosis. Clin Nucl Med 1984;9:638–9.
[145] Levin ML. Miliary tuberculosis masquerading as late infection in total hip replacement. Md Med J 1985;34:153–5.
[146] Wolfgang GL. Tuberculosis joint infection following total knee arthroplasty. Clin Orthop Relat Res 1985;201:162–6.
[147] Wray CC, Roy S. Arthroplasty in tuberculosis of the knee. Two cases of missed diagnosis. Acta Orthop Scand 1987;58:296–8.
[148] Lusk RH, Wienke EC, Milligan TW, Albus TE. Tuberculous and foreign-body granulomatous reactions involving a total knee prosthesis. Arthritis Rheum 1995;38:1325–7.
[149] Ueng WN, Shih CH, Hseuh S. Pulmonary tuberculosis as a source of infection after total hip arthroplasty. A report of two cases. Int Orthop 1995;19:55–9.
[150] Tokumoto JI, Follansbee SE, Jacobs RA. Prosthetic joint infection due to *Mycobacterium tuberculosis*: report of three cases. Clin Infect Dis 1995;21:134–6.
[151] Kreder HJ, Davey JR. Total hip arthroplasty complicated by tuberculous infection. J Arthroplasty 1996;11:111–4.
[152] Spinner RJ, Sexton DJ, Goldner RD, Levin LS. Periprosthetic infections due to *Mycobacterium tuberculosis* in patients with no prior history of tuberculosis. J Arthroplasty 1996;11:217–22.
[153] Baldini N, Toni A, Greggi T, Giunti A. Deep sepsis from *Mycobacterium tuberculosis* after total hip replacement. Case report. Arch Orthop Trauma Surg 1988;107:186–8.
[154] Hermans PW, Schuitema AR, Van Soolingen D, Verstynen CP, Bik EM, Thole JE, et al. Specific detection of *Mycobacterium tuberculosis* complex strains by polymerase chain reaction. J Clin Microbiol 1990;28:1204–13.
[155] Berbari EF, Hanssen AD, Duffy MC, Steckelberg JM, Osmon DR. Prosthetic joint infection due to *Mycobacterium tuberculosis*: a case series and review of the literature. Am J Orthop 1998;27:219–27.
[156] Krappel FA, Harland U. Failure of osteosynthesis and prosthetic joint infection due to *Mycobacterium tuberculosis* following a subtrochanteric fracture: a case report and review of the literature. Arch Orthop Trauma Surg 2000;120:470–2.
[157] Hugate R, Pellegrini VD. Reactivation of ancient tuberculous arthritis of the hip following total hip arthroplasty: a case report. J Bone Joint Surg Am 2002;84-A:101–5.
[158] Al-Shaikh R, Goodman SB. Delayed-onset *Mycobacterium tuberculosis* infection with staphylococcal superinfection after total knee replacement. Am J Orthop 2003;32:302–5.
[159] Fernández-Valencia JA, García S, Riba J. Presumptive infection of a total hip prosthesis by *Mycobacterium tuberculosis*: a case report. Acta Orthop Belg 2003;69:193–6.
[160] Marmor M, Parnes N, Dekel S. Tuberculosis infection complicating total knee arthroplasty: report of 3 cases and review of the literature. J Arthroplasty 2004;19:397–400.
[161] Kaya M, Nagoya S, Yamashita T, Niiro N, Fujita M. Peri-prosthetic tuberculous infection of the hip in a patient with no previous history of tuberculosis. J Bone Joint Surg Br 2006;88:394–5. https://doi.org/10.1302/0301-620X.88B3.17006.
[162] Khater FJ, Samnani IQ, Mehta JB, Moorman JP, Myers JW. Prosthetic joint infection by *Mycobacterium tuberculosis*: an unusual case report with literature review. South Med J 2007;100:66–9. https://doi.org/10.1097/01.smj.0000232972.50186.4c.
[163] Kadakia AP, Williams R, Langkamer VG. Tuberculous infection in a total knee replacement performed for medial tibial plateau fracture: a case report. Acta Orthop Belg 2007;73:661–4.
[164] Wang P-H, Shih K-S, Tsai C-C, Wang H-C. Pulmonary tuberculosis with delayed tuberculosis infection of total knee arthroplasty. J Formos Med Assoc 2007;106:82–5. https://doi.org/10.1016/S0929-6646(09)60221-7.
[165] Shanbhag V, Kotwal R, Gaitonde A, Singhal K. Total hip replacement infected with *Mycobacterium tuberculosis*. A case report with review of literature. Acta Orthop Belg 2007;73:268–74.
[166] Marschall J, Evison J-M, Droz S, Studer UC, Zimmerli S. Disseminated tuberculosis following total knee arthroplasty in an HIV patient. Infection 2008;36:274–8. https://doi.org/10.1007/s15010-007-7011-1.
[167] de Haan J, Vreeling AWJ, van Hellemondt GG. Reactivation of ancient joint tuberculosis of the knee following total knee arthroplasty after 61 years: a case report. Knee 2008;15:336–8. https://doi.org/10.1016/j.knee.2008.03.004.
[168] Maricevic A, Dogas Z, Goic-Barisić I, Barisić I. Reactivation of tuberculosis after total hip replacement—58 years after primary infection. Wien Klin Wochenschr 2008;120:642–3. https://doi.org/10.1007/s00508-008-1006-5.
[169] Lee H-J, Kim K-W, Kim KS, Ryu SH, Ha Y-C. Primary musculoskeletal *Mycobacterium* infection with large cystic masses after total hip arthroplasty. J Arthroplasty 2013;28:374.e1-3. https://doi.org/10.1016/j.arth.2012.05.009.
[170] Neogi DS, Kumar A, Yadav CS, Singh S. Delayed periprosthetic tuberculosis after total knee replacement: is conservative treatment possible? Acta Orthop Belg 2009;75:136–40.
[171] Upton A, Woodhouse A, Vaughan R, Newton S, Ellis-Pegler R. Evolution of central nervous system multidrug-resistant *Mycobacterium tuberculosis* and late relapse of cryptic prosthetic hip joint tuberculosis: complications during treatment of disseminated isoniazid-resistant tuberculosis in an immunocompromised host. J Clin Microbiol 2009;47:507–10. https://doi.org/10.1128/JCM.01473-08.
[172] Uppal S, Garg R. Tubercular infection presenting as sinus over ankle joint after knee replacement surgery. J Glob Infect Dis 2010;2:71–2. https://doi.org/10.4103/0974-777X.59257.
[173] Cansü E, Erdogan F, Ulusam AO. Incision infection with *Mycobacterium tuberculosis* after total hip arthroplasty without any primary tuberculosis focus. J Arthroplasty 2011;26:505.e1–3. https://doi.org/10.1016/j.arth.2009.11.025.
[174] Lee C-L, Wei Y-S, Ho Y-J, Lee C-H. Postoperative *Mycobacterium tuberculosis* infection after total knee arthroplasty. Knee 2009;16:87–9. https://doi.org/10.1016/j.knee.2008.09.006.
[175] De Nardo P, Corpolongo A, Conte A, Gentilotti E, Narciso P. Total hip replacement infected with *Mycobacterium tuberculosis* complicated by Addison disease and psoas muscle abscess: a case report. J Med Case Rep 2012;6:3. https://doi.org/10.1186/1752-1947-6-3.
[176] Walczak P, Rąpała K, Nowak-Misiak M, Pykało R, Truszczyńska A. Recurrence of tuberculosis after hip replacement 58 years after primary infection. Ortop Traumatol Rehabil 2012;14:189–96. https://doi.org/10.5604/15093492.992304.
[177] Klein GR, Jacquette GM. Prosthetic knee infection in the young immigrant patient—do not forget tuberculosis! J Arthroplasty 2012;27:1414.e1–4. https://doi.org/10.1016/j.arth.2011.09.020.
[178] Tekin Koruk S, Sipahioğlu S, Calişir C. Periprosthetic tuberculosis of the knee joint treated with antituberculosis drugs: a case report. Acta Orthop Traumatol Turc 2013;47:440–3.
[179] Harwin SF, Banerjee S, Issa K, Kapadia BH, Pivec R, Khanuja HS, et al. Tubercular prosthetic knee joint infection. Orthopedics 2013;36:e1464–9. https://doi.org/10.3928/01477447-20131021-35.
[180] Pérez-Jorge C, Valdazo-Rojo M, Blanco-García A, Esteban-Moreno J. *Mycobacterium tuberculosis* as cause of therapeutic failure in prosthetic joint infections. Enferm Infecc Microbiol Clin 2014;32:204–5. https://doi.org/10.1016/j.eimc.2013.04.022.
[181] Carrega G, Bartolacci V, Burastero G, Finocchio GC, Ronca A, Riccio G. Prosthetic joint infections due to *Mycobacterium tuberculosis*: a report of 5 cases. Int J Surg Case Rep 2013;4:178–81. https://doi.org/10.1016/j.ijscr.2012.11.011.
[182] Egües Dubuc C, Uriarte Ecenarro M, Errazquin Aguirre N, Belzunegui Otano J. Prosthesis infection by *Mycobacterium tuberculosis* in a patient with rheumatoid arthritis: a case report and literature review. Reumatol Clin 2014;10:347–9. https://doi.org/10.1016/j.reuma.2014.02.003.
[183] Mahale YJ, Aga N. Implant-associated *Mycobacterium tuberculosis* infection following surgical management of fractures: a retrospective observational study. Bone Joint J 2015;97-B:1279–83. https://doi.org/10.1302/0301-620X.97B9.35227.

[184] Veloci S, Mencarini J, Lagi F, Beltrami G, Campanacci DA, Bartoloni A, et al. Tubercular prosthetic joint infection: two case reports and literature review. Infection 2018;46:55–68. https://doi.org/10.1007/s15010-017-1085-1.
[185] World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: World Health Organization; 2014.
[186] Amphotericin B [accessed 02.03.18], https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Datasheet/6/a9528dat.pdf.
[187] National Center for Biotechnology Information. PubChem compound database; CID = 5280965, https://pubchem.ncbi.nlm.nih.gov/compound/5280965.
[188] National Center for Biotechnology Information. PubChem compound database; CID = 71616, https://pubchem.ncbi.nlm.nih.gov/compound/71616#section=NSC-Number.
[189] Cancidas_pi.pdf [Internet] [accessed 02.03.18], https://www.merck.com/product/usa/pi_circulars/c/cancidas/cancidas_pi.pdf.
[190] Sealy PI, Nguyen C, Tucci M, Benghuzzi H, Cleary JD. Delivery of antifungal agents using bioactive and nonbioactive bone cements. Ann Pharmacother 2009;43:1606–15. https://doi.org/10.1345/aph.1M143.
[191] Silverberg D, Kodali P, Dipersio J, Acus R, Askew M. In vitro analysis of antifungal impregnated polymethylmethacrylate bone cement. Clin Orthop Relat Res 2002;403:228–31.
[192] Łubkowski J, Błazejowski J, Czerwinski A, Borowski E. Thermal behaviour and stability of amphotericin B. Thermochimica Acta 1989;155:29–37. https://doi.org/10.1016/0040-6031(89)87133-3.
[193] Hamilton-Miller JM. The effect of pH and of temperature on the stability and bioactivity of nystatin and amphotericin B. J Pharm Pharmacol 1973;25:401–7.
[194] Adams AIH, Gosmann G, Schneider PH, Bergold AM. LC stability studies of voriconazole and structural elucidation of its major degradation product. Chromatographia 2009;69:115–22. https://doi.org/10.1365/s10337-009-1082-3.
[195] Roberts J, Bingham J, McLaren AC, McLemore R. Liposomal formulation decreases toxicity of amphotericin b in vitro and in vivo. Clin Orthop Relat Res 2015;473:2262–9. https://doi.org/10.1007/s11999-015-4232-y.
[196] VFEND® (voriconazole) for oral suspension. file:///C:/Users/amcla/Zotero/storage/U7UPQNX8/ShowLabeling.html.
[197] Geng L, Xu M, Yu L, Li J, Zhou Y, Wang Y, et al. Risk factors and the clinical and surgical features of fungal prosthetic joint infections: a retrospective analysis of eight cases. Exp Ther Med 2016;12:991–9. https://doi.org/10.3892/etm.2016.3353.
[198] Burgo FJ, Mengelle DE, Abraham A, Kremer G, Autorino CM. Periprosthetic fungal infection of a hip caused by *Trichosporon inkin*. Arthroplast Today 2018;4:24–6. https://doi.org/10.1016/j.artd.2017.05.005.
[199] Daniele L, Le M, Parr AF, Brown LM. *Scedosporium prolificans* septic arthritis and osteomyelitis of the hip joints in an immunocompetent patient: a case report and literature review. Case Rep Orthop 2017;2017:3809732. https://doi.org/10.1155/2017/3809732.
[200] Wang Q-J, Shen H, Zhang X-L, Jiang Y, Wang Q, Chen YS, et al. Staged reimplantation for the treatment of fungal peri-prosthetic joint infection following primary total knee arthroplasty. Orthop Traumatol Surg Res 2015;101:151–6. https://doi.org/10.1016/j.otsr.2014.11.014.
[201] Ong DC-G, Khan R, Golledge C, Carey Smith R. Case report: Eumycetoma and mycotic arthritis of the knee caused by *Arthrographis kalrae*. J Orthop 2015;12:S140–4. https://doi.org/10.1016/j.jor.2013.12.004.
[202] MacLean IS, Day SR, Moore CC, Browne JA. Blastomycosis infection of the knee treated with staged total knee arthroplasty. Knee 2015;22:669–71. https://doi.org/10.1016/j.knee.2015.03.003.
[203] Skedros JG, Keenan KE, Updike WS, Oliver MR. Failed reverse total shoulder arthroplasty caused by recurrent *Candida glabrata* infection with prior *Serratia marcescens* coinfection. Case Rep Infect Dis 2014;2014:142428. https://doi.org/10.1155/2014/142428.
[204] Reddy KJ, Shah JD, Kale RV, Reddy TJ. Fungal prosthetic joint infection after total knee arthroplasty. Indian J Orthop 2013;47:526–9. https://doi.org/10.4103/0019-5413.118213.
[205] Deelstra JJ, Neut D, Jutte PC. Successful treatment of *Candida albicans*-infected total hip prosthesis with staged procedure using an antifungal-loaded cement spacer. J Arthroplasty 2013;28:374.e5-8. https://doi.org/10.1016/j.arth.2012.04.034.
[206] Ueng SWN, Lee C-Y, Hu C, Hsieh P-H, Chang Y. What is the success of treatment of hip and knee candidal periprosthetic joint infection? Clin Orthop Relat Res 2013;471:3002–9. https://doi.org/10.1007/s11999-013-3007-6.
[207] Hwang BH, Yoon JY, Nam CH, Jung KA, Lee SC, Han CD, et al. Fungal periprosthetic joint infection after primary total knee replacement. J Bone Joint Surg Br 2012;94:656–9. https://doi.org/10.1302/0301-620X.94B5.28125.
[208] Hall GL, Villanueva-Siles E, Borzykowski RM, Gruson KI, Dorfman HD, Geller DS. Aspergillus osteomyelitis of the proximal humerus: a case report. Skeletal Radiol 2012;41:1021–5. https://doi.org/10.1007/s00256-012-1401-x.
[209] Denes E, Fiorenza F, Saint-Marcoux F, Megherbi M, Dupon M, Weinbreck P. Voriconazole stability in cement spacers. Med Mal Infect 2012;42:567–8. https://doi.org/10.1016/j.medmal.2012.07.007.
[210] Wu M-H, Hsu K-Y. Candidal arthritis in revision knee arthroplasty successfully treated with sequential parenteral-oral fluconazole and amphotericin B-loaded cement spacer. Knee Surg Sports Traumatol Arthrosc 2011;19:273–6. https://doi.org/10.1007/s00167-010-1211-4.
[211] Gottesman-Yekutieli T, Shwartz O, Edelman A, Hendel D, Dan M. *Pseudallescheria boydii* infection of a prosthetic hip joint—an uncommon infection in a rare location. Am J Med Sci 2011;342:250–3. https://doi.org/10.1097/MAJ.0b013e31821f9691.
[212] Wilkins RM, Hahn DB, Blum R. Bread mold osteomyelitis in the femur. Orthopedics 2009;32:362.
[213] Gaston G, Ogden J. *Candida glabrata* periprosthetic infection: a case report and literature review. J Arthroplasty 2004;19:927–30.
[214] Phelan DM, Osmon DR, Keating MR, Hanssen AD. Delayed reimplantation arthroplasty for candidal prosthetic joint infection: a report of 4 cases and review of the literature. Clin Infect Dis 2002;34:930–8. https://doi.org/10.1086/339212.
[215] Marra F, Robbins GM, Masri BA, Duncan C, Wasan KM, Kwong EH, et al. Amphotericin B-loaded bone cement to treat osteomyelitis caused by *Candida albicans*. Can J Surg 2001;44:383–6.